EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Breast Cancer Screening in Women With Multiple Sclerosis: A Mixed‐Methods Study

Chloe Pierret iD, Lou Philippe, Emmanuelle Leray iD

European Journal of Neurology · 2025

DOI: 10.1111/ene.70183 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Neurology, 2025. Verfasst von Chloe Pierret und 2 weiteren Autor:innen. Beteiligte Einrichtung: Rennes University, EHESP, CNRS, Inserm, ARENES UMR 6051, RSMS U 1309, Rennes, France. Hauptthemen laut MEDLINE: Multiple Sclerosis, Breast Neoplasms, Mammography, Early Detection of Cancer. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Fondation pour l'Aide à la Recherche sur la Sclérose en Plaques, EDMUS Foundation, Institut des Neurosciences Cliniques de Rennes.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

There is little information on breast cancer screening (BCS) practices in women with multiple sclerosis (WwMS).

Objective

To assess and compare BCS rates in WwMS and in the general population and identify barriers and facilitators.

Methods

In a 2012–2020 cohort study, we identified 47,166 WwMS without a history of cancer and matched them (up to 1:4) to 184,124 controls from the French national medico‐administrative database. Mammography rates were compared according to age, city‐level socio‐economic status, period, and DMT use. We used logistic and negative binomial models to identify factors associated with BCS adherence in WwMS. We also carried out semistructured interviews with 20 WwMS and analyzed them using the empirically inductive method.

Results

Compared with controls, fewer WwMS underwent BCS at least once (69.9% vs. 76.7%, p < 0.001) and had a lower biennial mammography rate (0.55 vs. 0.63; p < 0.001). Rate differences increased with age. Once stratified on DMT, age‐standardized rates only differed in the non‐treated group (0.51 vs. 0.64; p < 0.001). Factors associated with lower mammography rates in WwMS were city‐level socio‐economic status (mostdeprived vs. least deprived; IRR 0.88 95% CI [0.86–0.91]), long MS duration (16–25 years: 0.91 [0.89–0.94]; ref: ≤ 5) and hospitalization (MS‐related: 0.85 [0.82–0.88]; non‐MS‐related: 0.92 [0.89–0.94]). However, DMT use was associated with higher mammography rates (high efficacy: 1.17 [1.14–1.21]; moderate efficacy: 1.18 [1.16–1.20]). Barriers were physical disability and feeling of excessive medicalization. Facilitators were disability‐accessible care and perception of BCS as a routine procedure.

Conclusion

BCS among WwMS is suboptimal, especially among those not treated by DMT, and needs to be improved.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple SclerosisBreast NeoplasmsMammographyEarly Detection of CancerHumansFemaleMiddle AgedAdultCohort StudiesFranceAged

Stichwörter der Autor:innen

breast cancer screeningcohort studiesmedico‐administrative databasemixed‐methodsmultiple sclerosis

Autor:innen und Institutionen

  • Rennes University, EHESP, CNRS, Inserm, ARENES UMR 6051, RSMS U 1309, Rennes, France.

ORCID-Profile: Chloe Pierret, Emmanuelle Leray

Förderung

  • Fondation pour l'Aide à la Recherche sur la Sclérose en Plaques
  • EDMUS Foundation
  • Institut des Neurosciences Cliniques de Rennes
  • Matmut Paul Bennetot Foundation - INSPIRE Chair

Zitieren

APA

Pierret, C., Philippe, L., & Leray, E. (2025). Breast Cancer Screening in Women With Multiple Sclerosis: A Mixed‐Methods Study. European Journal of Neurology. https://doi.org/10.1111/ene.70183

Vancouver

Pierret C, Philippe L, Leray E. Breast Cancer Screening in Women With Multiple Sclerosis: A Mixed‐Methods Study. European Journal of Neurology. 2025. doi:10.1111/ene.70183

BibTeX
@article{Pierret2025,
  author = {Pierret, Chloe and Philippe, Lou and Leray, Emmanuelle},
  title = {Breast Cancer Screening in Women With Multiple Sclerosis: A Mixed‐Methods Study},
  journal = {European Journal of Neurology},
  year = {2025},
  doi = {10.1111/ene.70183}
}
Kostenlos starten →